Detalles de la búsqueda
1.
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.
Invest New Drugs
; 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38789848
2.
Challenges and Opportunities for In Vitro-In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation.
Drug Metab Dispos
; 51(12): 1591-1606, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751998
3.
Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Invest New Drugs
; 41(3): 402-410, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052729
4.
Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors.
Drug Metab Dispos
; 50(7): 989-997, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35504658
5.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 1042-1050, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35932388
6.
Effect of severe renal impairment on the pharmacokinetics of brigatinib.
Invest New Drugs
; 39(5): 1306-1314, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33742299
7.
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 39(2): 488-498, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33089874
8.
Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Drug Metab Dispos
; 48(3): 217-229, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31911485
9.
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 37(4): 666-673, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30397836
10.
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
Br J Clin Pharmacol
; 85(11): 2568-2579, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355467
11.
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Br J Clin Pharmacol
; 85(7): 1464-1473, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30845347
12.
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 36(3): 407-415, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28932928
13.
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Invest New Drugs
; 36(2): 248-258, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28852909
14.
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
Invest New Drugs
; 36(2): 240-247, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28819760
15.
Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
Br J Clin Pharmacol
; 84(1): 35-51, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28891222
16.
Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Cancer
; 122(16): 2524-33, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27192055
17.
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Br J Haematol
; 174(5): 748-59, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27196567
18.
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Invest New Drugs
; 34(3): 338-46, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27039387
19.
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Br J Clin Pharmacol
; 82(3): 728-38, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27121262
20.
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Invest New Drugs
; 33(4): 942-53, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26084989